Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
26
03
2020
revised:
01
07
2020
accepted:
18
08
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
5
1
2021
Statut:
epublish
Résumé
Several targeted therapies for cancer have been associated with cardiovascular toxicity. The evidence for this association has not been synthesized systematically nor has the quality of evidence been considered. We synthesized systematic review evidence of cardiovascular toxicity of individual targeted agents. We searched MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for systematic reviews with meta-analyses of cardiovascular outcomes for individual agents published to May 2020. We selected reviews according to prespecified eligibility criteria (International Prospective Register of Systematic Reviews CRD42017080014). We classified evidence of cardiovascular toxicity as sufficient, probable, possible, or indeterminate for specific cardiovascular outcomes based on statistical significance, study quality, and size. From 113 systematic reviews, we found at least probable systematic review evidence of cardiovascular toxicity for 18 agents, including high- and all-grade hypertension for bevacizumab, ramucirumab, axitinib, cediranib, pazopanib, sorafenib, sunitinib, vandetanib, aflibercept, abiraterone, and enzalutamide, and all-grade hypertension for nintedanib; high- and all-grade arterial thromboembolism (includes cardiac and/or cerebral events) for bevacizumab and abiraterone, high-grade arterial thromboembolism for trastuzumab, and all-grade arterial thromboembolism for sorafenib and tamoxifen; high- and all-grade venous thromboembolism (VTE) for lenalidomide and thalidomide, high-grade VTE for cetuximab and panitumumab, and all-grade VTE for bevacizumab; high- and all-grade left ventricular ejection fraction decline or congestive heart failure for bevacizumab and trastuzumab, and all-grade left ventricular ejection fraction decline/congestive heart failure for pazopanib and sunitinib; and all-grade corrected QT interval prolongation for vandetanib. Our review provides an accessible summary of the cardiovascular toxicity of targeted therapy to assist clinicians and patients when managing cardiovascular health.
Sections du résumé
BACKGROUND
BACKGROUND
Several targeted therapies for cancer have been associated with cardiovascular toxicity. The evidence for this association has not been synthesized systematically nor has the quality of evidence been considered. We synthesized systematic review evidence of cardiovascular toxicity of individual targeted agents.
METHODS
METHODS
We searched MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for systematic reviews with meta-analyses of cardiovascular outcomes for individual agents published to May 2020. We selected reviews according to prespecified eligibility criteria (International Prospective Register of Systematic Reviews CRD42017080014). We classified evidence of cardiovascular toxicity as sufficient, probable, possible, or indeterminate for specific cardiovascular outcomes based on statistical significance, study quality, and size.
RESULTS
RESULTS
From 113 systematic reviews, we found at least probable systematic review evidence of cardiovascular toxicity for 18 agents, including high- and all-grade hypertension for bevacizumab, ramucirumab, axitinib, cediranib, pazopanib, sorafenib, sunitinib, vandetanib, aflibercept, abiraterone, and enzalutamide, and all-grade hypertension for nintedanib; high- and all-grade arterial thromboembolism (includes cardiac and/or cerebral events) for bevacizumab and abiraterone, high-grade arterial thromboembolism for trastuzumab, and all-grade arterial thromboembolism for sorafenib and tamoxifen; high- and all-grade venous thromboembolism (VTE) for lenalidomide and thalidomide, high-grade VTE for cetuximab and panitumumab, and all-grade VTE for bevacizumab; high- and all-grade left ventricular ejection fraction decline or congestive heart failure for bevacizumab and trastuzumab, and all-grade left ventricular ejection fraction decline/congestive heart failure for pazopanib and sunitinib; and all-grade corrected QT interval prolongation for vandetanib.
CONCLUSIONS
CONCLUSIONS
Our review provides an accessible summary of the cardiovascular toxicity of targeted therapy to assist clinicians and patients when managing cardiovascular health.
Identifiants
pubmed: 33392444
doi: 10.1093/jncics/pkaa076
pii: pkaa076
pmc: PMC7768929
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkaa076Informations de copyright
© The Author(s) 2020. Published by Oxford University Press.
Références
Support Care Cancer. 2016 Sep;24(9):4057-74
pubmed: 27344327
Am J Hematol. 2011 Jan;86(1):18-24
pubmed: 21120867
Lung Cancer. 2011 Oct;74(1):89-97
pubmed: 21377753
Expert Opin Drug Saf. 2013 Sep;12(5):687-96
pubmed: 23560546
JAMA. 2008 Nov 19;300(19):2277-85
pubmed: 19017914
Cancer Treat Rev. 2011 Jun;37(4):312-20
pubmed: 20952131
BMJ Open. 2018 Jun 27;8(6):e021064
pubmed: 29950466
J Clin Oncol. 2011 Feb 20;29(6):632-8
pubmed: 21205755
PLoS One. 2015 Sep 02;10(9):e0136324
pubmed: 26331473
J Cancer Res Clin Oncol. 2014 Aug;140(8):1429-40
pubmed: 24770582
Chin Med J (Engl). 2015 May 5;128(9):1215-22
pubmed: 25947406
J Clin Epidemiol. 2015 May;68(5):574-83
pubmed: 25638457
Eur J Prev Cardiol. 2018 Mar;25(5):482-494
pubmed: 29376753
Sci Rep. 2015 Oct 27;5:15746
pubmed: 26503902
Expert Rev Clin Pharmacol. 2019 Aug;12(8):815-824
pubmed: 31287333
J Clin Epidemiol. 2012 Dec;65(12):1267-73
pubmed: 22959594
Exp Ther Med. 2016 May;11(5):1721-1733
pubmed: 27168794
Asian Pac J Cancer Prev. 2013;14(2):691-4
pubmed: 23621220
Int J Cardiol. 2019 Apr 1;280:163-175
pubmed: 30661849
Med Oncol. 2014 Dec;31(12):340
pubmed: 25416049
Contemp Oncol (Pozn). 2014;18(1):39-47
pubmed: 24876820
Oncotarget. 2017 Aug 8;8(48):84572-84578
pubmed: 29137449
J Breast Cancer. 2014 Mar;17(1):61-8
pubmed: 24744799
Clin Res Hepatol Gastroenterol. 2016 Dec;40(6):688-697
pubmed: 27339594
J Clin Oncol. 2010 May 1;28(13):2280-5
pubmed: 20351323
Thromb Haemost. 2007 Jun;97(6):1031-6
pubmed: 17549307
Int J Cancer. 2013 Jun 15;132(12):2967-74
pubmed: 23225494
Clin Transl Oncol. 2015 Sep;17(9):673-83
pubmed: 25990506
J Thorac Dis. 2018 Aug;10(8):5010-5022
pubmed: 30233875
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Br J Cancer. 2015 Jan 20;112(2):296-305
pubmed: 25349964
PLoS One. 2011;6(8):e22681
pubmed: 21829644
PLoS One. 2013 May 14;8(5):e64354
pubmed: 23691202
Ann Hematol. 2013 Jul;92(7):935-43
pubmed: 23455401
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008941
pubmed: 22786517
Syst Rev. 2012 Feb 09;1:2
pubmed: 22587842
Asian Pac J Cancer Prev. 2014;15(3):1313-20
pubmed: 24606458
Int J Clin Pharmacol Ther. 2017 Sep;55(9):720-727
pubmed: 28737130
Nat Rev Cardiol. 2015 Sep;12(9):547-58
pubmed: 25962976
Am J Hematol. 2011 Aug;86(8):657-62
pubmed: 21761431
Expert Opin Drug Saf. 2015 Feb;14(2):253-67
pubmed: 25494575
Oncotarget. 2017 Feb 7;8(6):10703-10713
pubmed: 27793044
Milbank Q. 2016 Sep;94(3):485-514
pubmed: 27620683
Cancer Invest. 2019;37(9):478-488
pubmed: 31557062
Breast. 2011 Dec;20(6):485-90
pubmed: 21784637
Lancet Neurol. 2015 Mar;14(3):263-73
pubmed: 25662901
Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242
pubmed: 24919460
Am J Hypertens. 2010 May;23(5):460-8
pubmed: 20186127
Am J Kidney Dis. 2007 Feb;49(2):186-93
pubmed: 17261421
Onco Targets Ther. 2016 May 30;9:3233-47
pubmed: 27313469
Mol Biol Rep. 2014 Oct;41(10):6575-82
pubmed: 25091939
J Natl Cancer Inst. 2015 Nov 18;108(3):
pubmed: 26582244
Biomed Res Int. 2016;2016:6848902
pubmed: 26949704
Tumour Biol. 2015 Mar;36(3):1933-41
pubmed: 25387808
J Exp Clin Cancer Res. 2011 May 12;30:54
pubmed: 21569417
Invest New Drugs. 2017 Aug;35(4):518-523
pubmed: 28285368
Cochrane Database Syst Rev. 2016 Apr 20;4:CD010816
pubmed: 27096326
Arch Gynecol Obstet. 2013 Sep;288(3):655-66
pubmed: 23543268
Ann Oncol. 2012 May;23(5):1130-1137
pubmed: 21976387
Cochrane Database Syst Rev. 2012 Nov 14;11:MR000030
pubmed: 23152285
Breast Cancer Res Treat. 2012 Oct;135(3):655-62
pubmed: 22875745
Br J Clin Pharmacol. 2014 Oct;78(4):748-62
pubmed: 24661224
Crit Rev Oncol Hematol. 2014 Nov;92(2):71-82
pubmed: 24878433
Leukemia. 2011 Apr;25(4):689-96
pubmed: 21233832
Crit Rev Oncol Hematol. 2015 May;94(2):228-37
pubmed: 25577572
PLoS One. 2013 Jul 04;8(7):e67929
pubmed: 23861835
Asian Pac J Cancer Prev. 2013;14(12):7111-6
pubmed: 24460260
Chin Med J (Engl). 2016 Feb 5;129(3):320-5
pubmed: 26831235
Lancet. 2011 Jan 8;377(9760):108-9
pubmed: 20630580
Clin Hypertens. 2019 Apr 1;25:5
pubmed: 30984412
World J Gastroenterol. 2015 Apr 28;21(16):5072-80
pubmed: 25945023
Int J Colorectal Dis. 2009 Jun;24(6):677-85
pubmed: 19184059
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243
pubmed: 22513938
Expert Rev Anticancer Ther. 2018 Feb;18(2):193-198
pubmed: 29257709
Br J Sports Med. 2017 Oct;51(20):1456-1458
pubmed: 28223307
Anticancer Drugs. 2012 Aug;23(7):731-8
pubmed: 22700001
BMJ. 2018 Oct 8;363:k3845
pubmed: 30297439
Cancer Treat Rev. 2013 Nov;39(7):753-8
pubmed: 23764179
Int J Evid Based Healthc. 2015 Sep;13(3):132-40
pubmed: 26360830
Evid Based Ment Health. 2018 Aug;21(3):95-100
pubmed: 30006442
Expert Opin Drug Discov. 2018 Jun;13(6):489-496
pubmed: 29621897
Core Evid. 2013;8:69-78
pubmed: 24115917
Trends Pharmacol Sci. 2005 Mar;26(3):119-24
pubmed: 15749156
PLoS One. 2014 Jul 15;9(7):e102484
pubmed: 25025282
Eur Urol. 2015 Sep;68(3):386-96
pubmed: 25484142
Drug Saf. 2013 Jun;36(6):413-26
pubmed: 23620170
J Chemother. 2013 Jun;25(3):170-5
pubmed: 23783142
Cancer Treat Rev. 2008 Aug;34(5):442-52
pubmed: 18381234
J Exp Clin Cancer Res. 2010 May 26;29:58
pubmed: 20504361
Ann Oncol. 2017 Mar 1;28(3):487-496
pubmed: 27998966
Ann Oncol. 2011 Jun;22(6):1404-1412
pubmed: 21115602
Colorectal Dis. 2010 May;12(5):399-406
pubmed: 19508512
Anticancer Drugs. 2010 Mar;21(3):326-32
pubmed: 20016366
Cochrane Database Syst Rev. 2014 Oct 01;(10):MR000035
pubmed: 25271098
Hepatol Int. 2016 May;10(3):501-10
pubmed: 26856326
JAMA. 2011 Feb 2;305(5):487-94
pubmed: 21285426
Expert Opin Drug Saf. 2018 Sep;17(9):875-892
pubmed: 30126304
Clin Drug Investig. 2014 Oct;34(10):681-90
pubmed: 25096848
Oncotarget. 2016 Oct 11;7(41):67661-67673
pubmed: 27602778
BMJ. 1992 Jul 25;305(6847):225-6
pubmed: 1392827
Eur J Cancer. 2017 Oct;84:88-101
pubmed: 28800492
J Chemother. 2015;27(6):365-70
pubmed: 25872413
Cochrane Database Syst Rev. 2011 Sep 07;(9):CD007930
pubmed: 21901715
Indian J Cancer. 2014 Mar;51 Suppl 3:e95-8
pubmed: 25818743
Ther Adv Med Oncol. 2016 Jul;8(4):267-75
pubmed: 27482286
BMC Cancer. 2007 Aug 08;7:153
pubmed: 17686164
Br J Clin Pharmacol. 2013 Sep;76(3):348-57
pubmed: 23617405
Clin Oncol (R Coll Radiol). 2013 Jan;25(1):e7-e15
pubmed: 23177099
Int J Hematol. 2019 Jan;109(1):79-90
pubmed: 30291558
Clin Drug Investig. 2015 Apr;35(4):221-8
pubmed: 25697774
Clin Transl Oncol. 2016 Aug;18(8):848-58
pubmed: 26519363
Tumour Biol. 2014 Dec;35(12):11741-50
pubmed: 25417200
J Cancer Res Ther. 2016 Apr-Jun;12(2):775-81
pubmed: 27461650
Oncotarget. 2017 Dec 6;8(69):113318-113330
pubmed: 29371913
Crit Rev Oncol Hematol. 2014 Dec;92(3):194-207
pubmed: 25028151
Eur J Cancer. 2015 Sep;51(14):1970-7
pubmed: 26169016
Dig Liver Dis. 2011 Apr;43(4):286-94
pubmed: 21146479
Oncotarget. 2017 Mar 21;8(12):19923-19933
pubmed: 28199966
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD005392
pubmed: 19588372
Oncologist. 2008 Jun;13(6):620-30
pubmed: 18586917
PLoS One. 2015 Mar 20;10(3):e0117344
pubmed: 25794005
Expert Opin Drug Saf. 2015;14(11):1661-71
pubmed: 26461271
J Am Coll Cardiol. 2015 Sep 8;66(10):1160-78
pubmed: 26337996
BioDrugs. 2018 Dec;32(6):585-606
pubmed: 30499082
J Clin Oncol. 2011 Sep 1;29(25):3450-6
pubmed: 21810682
J Gen Intern Med. 2003 Nov;18(11):937-47
pubmed: 14687281
BMC Med Res Methodol. 2007 Feb 15;7:10
pubmed: 17302989
Jpn J Clin Oncol. 2018 Dec 1;48(12):1058-1069
pubmed: 30272196
NPJ Precis Oncol. 2017 Sep 12;1(1):31
pubmed: 29872712
Am Health Drug Benefits. 2016 Jun;9(4):221-32
pubmed: 27688834
Clin Drug Investig. 2016 Jan;36(1):27-39
pubmed: 26547200
Ther Clin Risk Manag. 2019 Feb 15;15:293-302
pubmed: 30858709
BMC Cancer. 2016 Aug 24;16:677
pubmed: 27558497
Breast J. 2011 Jan-Feb;17(1):109-11
pubmed: 21129096
Chin Med J (Engl). 2014;127(3):538-46
pubmed: 24451964
PLoS One. 2014 Jun 19;9(6):e100305
pubmed: 24945380
Clin Drug Investig. 2013 Nov;33(11):779-88
pubmed: 23979925
PLoS One. 2014 Dec 02;9(12):e112530
pubmed: 25460347
Parkinsonism Relat Disord. 2016 Feb;23:1-9
pubmed: 26739246
Leuk Lymphoma. 2014 Sep;55(9):2024-31
pubmed: 24067138
Oncologist. 2010;15(11):1179-91
pubmed: 21045188
Res Synth Methods. 2017 Mar;8(1):92-108
pubmed: 28074553
Ann Oncol. 2014 Feb;25(2):455-61
pubmed: 24478322
Oncotarget. 2017 Dec 23;9(18):14619-14629
pubmed: 29581868
Leukemia. 2008 Feb;22(2):414-23
pubmed: 18094721
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):458-66
pubmed: 23060390
Acta Oncol. 2010 Apr;49(3):287-97
pubmed: 20156114
Crit Rev Oncol Hematol. 2016 May;101:12-20
pubmed: 26971992
Oncotarget. 2016 Mar 15;7(11):13221-7
pubmed: 26657509
Syst Rev. 2017 Jul 18;6(1):145
pubmed: 28720141
Br J Clin Pharmacol. 2013 Apr;75(4):919-30
pubmed: 22882307
Ann Pharmacother. 2020 Jun;54(6):517-525
pubmed: 31855061
J Am Heart Assoc. 2017 Aug 10;6(8):
pubmed: 28862931
BMC Cancer. 2012 Mar 13;12:89
pubmed: 22414244
Lung Cancer. 2014 Feb;83(2):211-8
pubmed: 24332319
Clin Drug Investig. 2018 Dec;38(12):1109-1123
pubmed: 30327999
PLoS One. 2013 Dec 04;8(12):e81858
pubmed: 24324725
Asian Pac J Cancer Prev. 2014;15(14):5691-6
pubmed: 25081687
JAMA Cardiol. 2016 Dec 1;1(9):1066-1072
pubmed: 27541948
Chin Med J (Engl). 2013;126(17):3348-55
pubmed: 24033963
Future Oncol. 2014 Oct;10(12):1981-92
pubmed: 25386814
Clin Drug Investig. 2014 Apr;34(4):231-40
pubmed: 24493142
Tumour Biol. 2014 Oct;35(10):10409-18
pubmed: 25053599
Oncotarget. 2017 May 23;8(31):51492-51506
pubmed: 28881662
Eur J Clin Pharmacol. 2010 Aug;66(8):813-21
pubmed: 20401474
Eur J Epidemiol. 2020 Jan;35(1):49-60
pubmed: 31720912
Invest New Drugs. 2011 Feb;29(1):182-8
pubmed: 19756376
Cancer Biother Radiopharm. 2013 Sep;28(7):501-9
pubmed: 23768086
PLoS One. 2012;7(2):e30353
pubmed: 22363427
J Natl Cancer Inst. 1994 Oct 19;86(20):1534-9
pubmed: 7932809
PLoS One. 2013;8(1):e51780
pubmed: 23349675
Lancet Oncol. 2008 Feb;9(2):117-23
pubmed: 18221915
Int J Cancer. 2016 Nov 15;139(10):2370-80
pubmed: 27450994
Sci Rep. 2015 Oct 01;5:14698
pubmed: 26423913
BMC Cancer. 2019 Jan 14;19(1):60
pubmed: 30642291
BMC Cancer. 2018 Nov 26;18(1):1170
pubmed: 30477458
J Hum Hypertens. 2013 Oct;27(10):601-11
pubmed: 23636006
Cancer Treat Rev. 2017 Sep;59:123-131
pubmed: 28818671
J Clin Gastroenterol. 2013 Nov-Dec;47(10):871-80
pubmed: 24100749
J Oncol. 2012;2012:417673
pubmed: 23008712
JAMA Oncol. 2019 Sep 5;:
pubmed: 31486837
J Clin Epidemiol. 2014 Dec;67(12):1302-8
pubmed: 25281222
Cancer Chemother Pharmacol. 2013 Feb;71(2):431-9
pubmed: 23178953
Onco Targets Ther. 2016 Apr 21;9:2421-8
pubmed: 27143937
Oncologist. 2016 May;21(5):547-54
pubmed: 27026675
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922781
PLoS One. 2013 Jun 20;8(6):e66721
pubmed: 23818962
Eur J Clin Pharmacol. 2014 Feb;70(2):225-31
pubmed: 24150533
Acta Oncol. 2009;48(1):9-17
pubmed: 18752081
Int J Cancer. 2013 Nov;133(9):2245-52
pubmed: 23629633
Ann Oncol. 2013 Jan;24(1):20-30
pubmed: 23180113
Cancer Chemother Pharmacol. 2017 Sep;80(3):487-495
pubmed: 28695268
Evid Based Med. 2016 Aug;21(4):125-7
pubmed: 27339128
Acta Oncol. 2012 Feb;51(2):151-6
pubmed: 22085338
Asian Pac J Cancer Prev. 2011;12(11):2857-63
pubmed: 22393954
Oncol Lett. 2015 Mar;9(3):1351-1358
pubmed: 25663912
BMC Med Res Methodol. 2019 Nov 4;19(1):203
pubmed: 31684874
Oncotarget. 2017 May 9;8(19):31318-31328
pubmed: 28412743
Clin Genitourin Cancer. 2018 Jun;16(3):e645-e653
pubmed: 29339044
J Clin Epidemiol. 2009 Oct;62(10):1013-20
pubmed: 19230606
Med Oncol. 2015 Feb;32(2):473
pubmed: 25603953
Onco Targets Ther. 2018 Oct 02;11:6405-6414
pubmed: 30323618
Tumour Biol. 2017 Jul;39(7):1010428317714897
pubmed: 28714372